Actively Recruiting
Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF
Led by The Cleveland Clinic · Updated on 2026-05-08
1000
Participants Needed
1
Research Sites
350 weeks
Total Duration
On this page
Sponsors
T
The Cleveland Clinic
Lead Sponsor
U
University of Glasgow
Collaborating Sponsor
AI-Summary
What this Trial Is About
EAGLE-HF (Early Assessment and initiation of GuideLine-directed Evidence-based management-HF) is a prospective single site study of a multinational, unblinded, randomized-controlled, longitudinal trial called SYMPHONY. Primary, secondary and exploratory outcomes that are part of SYMPHONY are not described herein as they replicate SYMPHONY outcomes. Data associated with SYMPHONY outcomes will be sent to the SYMPHONY coordinating center. In EAGLE-HF, site investigators will examine if a new-onset heart failure (HF) diagnosis are asscoiated with social determinants of health (6 factors), social vulnerability index and distressed community indices. In addition, for patients diagnosed with HFrEF, prescribing patterns (use of and dose of) core HF medications will be assessed for association with physician practice type and medical provider type. Finally, (among participants in the SYMPHONY Active arm, an optimal NTproBNP cut-point will be assessed for diagnosis of HF based on social determinants of health, social vulnerability index, distressed community index, HF risk factors and medical comorbidities.
CONDITIONS
Official Title
Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients enrolled in SYMPHONY
- At least 40 years old at enrollment
- Willing to sign informed consent
- Specific Activity Scale results matching NYHA-FC score II-IV
- Have at least 2 documented heart failure risk factors, including established cardiovascular disease, diabetes (type I or II), persistent or permanent atrial fibrillation, previous ischemic or embolic stroke, peripheral arterial disease, chronic kidney disease, loop diuretic use >30 days in prior year, or chronic obstructive pulmonary disease
You will not qualify if you...
- Unable to give informed consent due to cognitive impairment, language barriers, or inability to understand consent
- Previous diagnosis of heart failure of any type or cause
- Receiving renal replacement therapy
- Unable to travel to Cleveland Clinic for biomarker or handheld echocardiogram with AI (e.g., receiving hospice or skilled nursing care)
- Considered unsuitable by investigators, including history of left breast mastectomy with reconstruction preventing AI echocardiogram use or minimal prior Cleveland Clinic medical visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
N
Nancy M Albert, PhD
CONTACT
M
Michelle Levay, MSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here